Dr. Christopher Andrew Yasenchak, MD

Dr. Yasenchak practices at Willamette Valley Cancer Institute and Research Center in Eugene, Oregon.

Dr. Yasenchak's NPI, 1508830670, was assigned on February 15, 2006. Dr. Yasenchak graduated from Pennsylvania State University College of Medicine in 1999. Dr. Yasenchak holds Oregon license MD27063.

Dr. Yasenchak's primary practice is Willamette Valley Cancer Institute and Research Center, at 520 Country Club Rd, Eugene, OR 97401 in Lane County. The practice phone is (541) 683-5001.

Dr. Yasenchak's primary practice is Willamette Valley Cancer Institute and Research Center in Eugene, Oregon. Dr. Yasenchak is also affiliated with PeaceHealth Sacred Heart Medical Center RiverBend. The medical group on file is Willamette Valley Cancer Institute & Research Center. Dmand AI also links Dr. Yasenchak to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Yasenchak practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Yasenchak's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Yasenchak's licenses on file in 2 states: Oregon and Washington.

CMS data shows 73,350 Medicare services from Dr. Yasenchak across 67 procedure codes in 2024, for 610 Medicare patients. Medicare paid $1,095,653 for them.

CMS counts 610 Medicare patients who saw Dr. Yasenchak in 2024. The largest group is 65 to 74, with 292 patients. 68% of them have high blood pressure, and 61% have high cholesterol. 13% are also on Medicaid. Their average risk score is 2.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Yasenchak's median patient age at 71, with 55% women.

In 2024, Dr. Yasenchak wrote 1,454 Medicare Part D claims for 221 patients. 75% of them were for generic drugs. CMS names the drug for 1,186 of them, across 36 drugs with 11 or more claims each, at $3,716,298 in total drug cost. In 2023, CMS named 1,110 claims across 31 drugs.

Dr. Yasenchak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Yasenchak as offering telehealth.

Dmand AI links 10 papers to Dr. Yasenchak, published from 2015 to 2025. 2015 was the busiest year, with 2. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Hodgkin Disease and Brentuximab Vedotin. Dr. Yasenchak has published most often in Blood. Dr. Yasenchak's most frequent co-authors are Michelle A. Fanale, MD, Rodolfo Eduardo Bordoni, MD and Rangaswamy Akhanda Chintapatla, MD.

Dmand AI links Dr. Yasenchak to 8 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Multiple Myeloma, Blood Protein Disorders and Lymphoma, Large B-Cell, Diffuse. Seagen Inc. sponsors the most, 5. Open Payments lists research payments to Dr. Yasenchak that name 1 trial.

CMS Open Payments shows 82 general payments to Dr. Yasenchak from 14 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 68% of the total. BeiGene, Ltd. paid the most, $48,665. It also lists 17 research payments totaling $18,700 from 2024 to 2025, naming 1 clinical trial.

Dr. Yasenchak graduated from Pennsylvania State University College of Medicine in 1999.